Claims for Patent: 7,910,132

Summary for Patent: 7,910,132

Title:	Pharmaceutical composition for the treatment of acute disorders
Abstract:	A pharmaceutical composition for the treatment of acute disorders is described. The composition comprises an essentially water-free, ordered mixture of at least one pharmaceutically active agent in the form of microparticles which are adhered to the surfaces of carrier particles which are substantially larger than the particles of the active agent or agents, and are essentially water-soluble, in combination with the bioadhesion and/or mucoadhesion promoting agent. The invention also relates to a method for preparing the composition and to the use of the composition for the treatment of acute disorders.
Inventor(s):	Pettersson; Anders (Kode, SE), Nystrom; Christer (Lidingo, SE)
Assignee:	Orexo AB (Uppsala, SE)
Application Number:	11/544,660
Patent Claims:	1. A method of treating breakthrough pain in an individual receiving at least one analgesic for treatment of pain and experiencing the breakthrough pain comprising periods of inadequate analgesia, the method comprising providing a pharmaceutical composition comprising a pharmaceutically effective amount of fentanyl or a pharmaceutically acceptable salt thereof in a dosage form comprising a tablet sized for placement under a tongue, the fentanyl or the pharmaceutically acceptable salt thereof comprising particles having a maximum weight based mean particle size of about 24 .mu.m, the pharmaceutical composition also comprising a bioadhesion and/or mucoadhesion promoting agent constituted to promote adhesion of the fentanyl or the pharmaceutically acceptable salt thereof to mucous membrane to allow an uptake of the fentanyl through mucous membrane under the tongue, and providing sublingual administration of the pharmaceutical composition to treat the breakthrough pain by placing the tablet under the tongue of the individual to allow the uptake of the fentanyl through the mucous membrane giving rise to a rapid update of the fentanyl within about five minutes. 2. A method according to claim 1 wherein the fentanyl or the pharmaceutically acceptable salt thereof comprise between about 0.05 and 20 weight percent of the pharmaceutical composition. 3. A method of treating breakthrough pain in an individual receiving at least one analgesic for treatment of pain and experiencing the breakthrough pain comprising periods of inadequate analgesia, the method comprising providing a pharmaceutical composition comprising a pharmaceutically effective amount of fentanyl or a pharmaceutically acceptable salt thereof in a dosage form comprising a tablet sized for placement under a tongue, the fentanyl or the pharmaceutically acceptable salt thereof comprising particles having a maximum weight based mean particle size of about 24 .mu.m, the pharmaceutical composition including between about 0.05 and 20 mg of the fentanyl or the pharmaceutically acceptable salt thereof in a dose unit of the pharmaceutical composition, the pharmaceutical composition also comprising a bioadhesion and/or mucoadhesion promoting agent constituted to promote adhesion of the fentanyl or the pharmaceutically acceptable salt thereof to mucous membrane to allow an uptake of the fentanyl through mucous membrane under the tongue, and providing sublingual administration of the pharmaceutical composition to treat the breakthrough pain by placing the tablet under the tongue of the individual to allow the uptake of the fentanyl through the mucous membrane giving rise to a rapid uptake of the fentanyl within about five minutes. 4. A method according to claim 1 or 3 wherein the bioadhesion and/or mucoadhesion promoting agent comprises particles having a particle size of between about 1 and 100 .mu.m. 5. A method according to claim 1 or 3 wherein the bioadhesion and/or mucoadhesion promoting agent comprises between about 0.1 and 25 weight percent of the pharmaceutical composition. 6. A method according to claim 3 wherein the bioadhesion and/or mucoadhesion promoting agent comprises particles having a particle size of between about 1 and 100 .mu.m, and wherein the bioadhesion and/or mucoadhesion promoting agent comprises between about 0.1 and 25 weight percent of the pharmaceutical composition. 7. A method of treating breakthrough pain in an individual receiving at least one analgesic for treatment of pain and experiencing the breakthrough pain comprising periods of inadequate analgesia, the method comprising providing a pharmaceutical composition comprising a pharmaceutically effective amount of fentanyl or a pharmaceutically acceptable salt thereof in a dosage form comprising a tablet sized for placement under a tongue, the fentanyl or the pharmaceutically acceptable salt thereof comprising particles having a maximum weight based mean particle size of about 24 .mu.m, the pharmaceutical composition including between about 0.05 and 20 mg of the fentanyl or the pharmaceutically acceptable salt thereof in a dose unit of the pharmaceutical composition, the pharmaceutical composition further comprising a bioadhesion and/or mucoadhesion promoting agent constituted to promote adhesion of the fentanyl or a pharmaceutically acceptable salt thereof to mucous membrane to allow an uptake of the fentanyl through mucous membrane under the tongue, the bioadhesion and/or mucoadhesion promoting agent comprising particles having a particle size of between about 1 and 100 .mu.m, and providing sublingual administration of the pharmaceutical composition to treat the breakthrough pain by placing the tablet under the tongue of the individual to allow the uptake of the fentanyl through the mucous membrane giving rise to a rapid uptake of the fentanyl within about five minutes. 8. A method of treating breakthrough pain in an individual receiving at least one analgesic for treatment of pain and experiencing the breakthrough pain comprising periods of inadequate analgesia, the method comprising providing a pharmaceutical composition comprising a pharmaceutically effective amount of fentanyl or a pharmaceutically acceptable salt thereof in a dosage form comprising a tablet sized for placement under a tongue, the fentanyl or the pharmaceutically acceptable salt thereof comprising particles having a maximum weight based mean particle size of about 24 .mu.m, the pharmaceutical composition further comprising a bioadhesion and/or mucoadhesion promoting agent constituted to promote adhesion of the fentanyl or the pharmaceutically acceptable salt thereof to mucous membrane to allow an uptake of the fentanyl through mucous membrane under the tongue, the bioadhesion and/or mucoadhesion promoting agent comprising particles having a particle size of between 1 and 100 .mu.m, the bioadhesion and/or mucoadhesion promoting agent comprising between about 0.1 and 25 weight percent of the pharmaceutical composition, and providing sublingual administration of the pharmaceutical composition to treat the breakthrough pain by placing the tablet under the tongue of the individual to allow the uptake of the fentanyl through the mucous membrane giving rise to a rapid uptake of the fentanyl within about five minutes. 9. A method according to claim 7 wherein the bioadhesion and/or mucoadhesion promoting agent comprise between about 0.1 and 25 weight percent of the pharmaceutical composition. 10. A method according to claim 1 or 3 or 7 or 8 wherein the pharmaceutical composition comprises a pharmaceutically effective amount of fentanyl citrate, and wherein the sublingual administration provided allows the uptake of the fentanyl through the mucous membrane giving rise to a rapid uptake of the fentanyl within about five minutes. 11. A method according to claim 8 wherein the fentanyl or the pharmaceutically acceptable salt thereof comprise between about 0.05 and 20 weight percent of the pharmaceutical composition.